A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs GS 9674 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 13 Jul 2017 Planned number of patients changed from 125 to 140.
    • 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 23 May 2017 This trial has been completed in Austria as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top